Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia

AI Briefing

• – Terremoto Biosciences closes $108M Series C financing to advance AKT1-inhibitors in oncology and hereditary hemorrhagic telangiectasia.
• – The round includes investments from RA Capital Management, Deep Track Capital, Osage University Partners, BeOne Medicines, and existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.
• – The company will use the funding to further develop its pipeline of highly targeted, small molecule medicines.